

# Karyopharm Granted U.S. Composition-of-Matter Patent for Selinexor (KPT-330)

NEWTON, Mass., April 13, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the issuance of U.S. Patent No. 8,999,996 entitled "Hydrazide Containing Nuclear Transport Modulators and Uses Thereof." This patent, which will expire in 2032 absent any patent term extensions, covers the composition-of-matter of Karyopharm's lead product candidate, selinexor (KPT-330), a first-in-class, oral SINE™ compound, as well as certain other compositions and related methods. Selinexor is being evaluated in multiple registration-directed and other later stage trials in patients with relapsed and/or refractory hematological and solid tumor malignancies.

"XPO1 inhibition with SINE compounds such as selinexor has the potential to provide a novel, oral therapy that selectively enables tumor suppressor proteins to remain in the nucleus, promoting cancer cell apoptosis while sparing normal cells. This selectivity for cancer cells offers the potential to minimize side effects and broadens its therapeutic scope across many cancer types, including both hematological and solid tumor malignancies," said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. "We remain focused on seeking approval and launching selinexor as expeditiously as possible in North America and Western Europe, initially as a single agent in high-unmet need hematologic indications, with three on-going registration-directed clinical trials currently underway and additional registration-directed studies planned in 2015."

## About Selinexor

Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. Over 700 patients have been treated with selinexor in Phase 1 and Phase 2 clinical trials in advanced hematologic malignancies and solid tumors. Karyopharm has initiated three registration-directed clinical trials of selinexor, one in older patients with acute myeloid leukemia (SOPRA), one in patients with Richter's transformation (SIRRT) and one in patients with diffuse large B-cell lymphoma (SADAL). Karyopharm plans to initiate a single-arm trial of selinexor in multiple myeloma in the first half of 2015 that is also intended to be registration-directed. In solid tumors, Karyopharm plans to initiate a Phase 3 pivotal trial of selinexor to treat liposarcoma during the second half of 2015. Other potential registration-directed trials in hematological and solid tumor indications are being evaluated. Additional Phase 1 and Phase 2 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform the company's clinical development priorities for selinexor. The latest clinical trial information for selinexor is available at [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

## About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). SINE™ compounds have also shown biological activity in models of cancer, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit [www.karyopharm.com](http://www.karyopharm.com).

## Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the therapeutic potential of and potential clinical development plans for Karyopharm's drug candidates, including the timing of initiation of certain trials and of the reporting of data from such trials. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any of Karyopharm's SINE™ compounds, including selinexor (KPT-330) or any PAK4 inhibitor, or any other drug candidate that Karyopharm is developing will successfully complete necessary preclinical and clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties

relating to a number of other factors, including the following: Karyopharm's results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Karyopharm's ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; development of drug candidates by Karyopharm's competitors for diseases in which Karyopharm is currently developing its drug candidates; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any drug candidates it is developing. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2014, which is on file with the Securities and Exchange Commission (SEC) as of March 13, 2015. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Justin Renz

(617) 658-0574

[jrenz@karyopharm.com](mailto:jrenz@karyopharm.com)

Gina Nugent

(617) 460-3579

[nugentcomm@aol.com](mailto:nugentcomm@aol.com)

Source: Karyopharm Therapeutics

News Provided by Acquire Media

---

<https://investors.karyopharm.com/2015-04-13-Karyopharm-Granted-U-S-Composition-of-Matter-Patent-for-Selinexor-KPT-330>